These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
384 related articles for article (PubMed ID: 23888683)
1. [Roles of targeting Ras/Raf/MEK/ERK signaling pathways in the treatment of esophageal carcinoma]. Chang YS; Liu JC; Fu HQ; Yu BT; Zou SB; Wu QC; Wan L Yao Xue Xue Bao; 2013 May; 48(5):635-41. PubMed ID: 23888683 [TBL] [Abstract][Full Text] [Related]
2. Bromodomain containing protein represses the Ras/Raf/MEK/ERK pathway to attenuate human hepatoma cell proliferation during HCV infection. Zhang Q; Wei L; Yang H; Yang W; Yang Q; Zhang Z; Wu K; Wu J Cancer Lett; 2016 Feb; 371(1):107-16. PubMed ID: 26620707 [TBL] [Abstract][Full Text] [Related]
3. Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma. Yang R; Piperdi S; Gorlick R Clin Cancer Res; 2008 Oct; 14(20):6396-404. PubMed ID: 18927278 [TBL] [Abstract][Full Text] [Related]
4. Genetic Validation of Cell Proliferation via Ras-Independent Activation of the Raf/Mek/Erk Pathway. Lechuga CG; Simón-Carrasco L; Jacob HK; Drosten M Methods Mol Biol; 2017; 1487():269-276. PubMed ID: 27924574 [TBL] [Abstract][Full Text] [Related]
5. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells. Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520 [TBL] [Abstract][Full Text] [Related]
6. CrkL plays a role in SDF-1-induced activation of the Raf-1/MEK/Erk pathway through Ras and Rac to mediate chemotactic signaling in hematopoietic cells. Arai A; Aoki M; Weihua Y; Jin A; Miura O Cell Signal; 2006 Dec; 18(12):2162-71. PubMed ID: 16781119 [TBL] [Abstract][Full Text] [Related]
7. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. Steelman LS; Franklin RA; Abrams SL; Chappell W; Kempf CR; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo P; Ruvolo V; Evangelisti C; Martelli AM; McCubrey JA Leukemia; 2011 Jul; 25(7):1080-94. PubMed ID: 21494257 [TBL] [Abstract][Full Text] [Related]
8. Induction of beta3-integrin gene expression by sustained activation of the Ras-regulated Raf-MEK-extracellular signal-regulated kinase signaling pathway. Woods D; Cherwinski H; Venetsanakos E; Bhat A; Gysin S; Humbert M; Bray PF; Saylor VL; McMahon M Mol Cell Biol; 2001 May; 21(9):3192-205. PubMed ID: 11287623 [TBL] [Abstract][Full Text] [Related]
9. Interferon-alpha2b reduces phosphorylation and activity of MEK and ERK through a Ras/Raf-independent mechanism. Romerio F; Riva A; Zella D Br J Cancer; 2000 Aug; 83(4):532-8. PubMed ID: 10945503 [TBL] [Abstract][Full Text] [Related]
10. Nobiletin induces inhibitions of Ras activity and mitogen-activated protein kinase kinase/extracellular signal-regulated kinase signaling to suppress cell proliferation in C6 rat glioma cells. Aoki K; Yokosuka A; Mimaki Y; Fukunaga K; Yamakuni T Biol Pharm Bull; 2013; 36(4):540-7. PubMed ID: 23546290 [TBL] [Abstract][Full Text] [Related]
11. Flagellin and lipopolysaccharide stimulate the MEK-ERK signaling pathway in chicken heterophils through differential activation of the small GTPases, Ras and Rap1. Kogut MH; Genovese KJ; He H Mol Immunol; 2007 Mar; 44(7):1729-36. PubMed ID: 17045653 [TBL] [Abstract][Full Text] [Related]
12. Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells. Ambrosini G; Cheema HS; Seelman S; Teed A; Sambol EB; Singer S; Schwartz GK Mol Cancer Ther; 2008 Apr; 7(4):890-6. PubMed ID: 18413802 [TBL] [Abstract][Full Text] [Related]
13. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Chang F; Steelman LS; Lee JT; Shelton JG; Navolanic PM; Blalock WL; Franklin RA; McCubrey JA Leukemia; 2003 Jul; 17(7):1263-93. PubMed ID: 12835716 [TBL] [Abstract][Full Text] [Related]
14. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Chappell WH; Steelman LS; Long JM; Kempf RC; Abrams SL; Franklin RA; Bäsecke J; Stivala F; Donia M; Fagone P; Malaponte G; Mazzarino MC; Nicoletti F; Libra M; Maksimovic-Ivanic D; Mijatovic S; Montalto G; Cervello M; Laidler P; Milella M; Tafuri A; Bonati A; Evangelisti C; Cocco L; Martelli AM; McCubrey JA Oncotarget; 2011 Mar; 2(3):135-64. PubMed ID: 21411864 [TBL] [Abstract][Full Text] [Related]
15. Leukemia inhibitory factor can mediate Ras/Raf/MEK/ERK-induced growth inhibitory signaling in medullary thyroid cancer cells. Arthan D; Hong SK; Park JI Cancer Lett; 2010 Nov; 297(1):31-41. PubMed ID: 20570039 [TBL] [Abstract][Full Text] [Related]
16. Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Kolch W Nat Rev Mol Cell Biol; 2005 Nov; 6(11):827-37. PubMed ID: 16227978 [TBL] [Abstract][Full Text] [Related]
17. Recent developments in anti-cancer agents targeting the Ras/Raf/ MEK/ERK pathway. Wong KK Recent Pat Anticancer Drug Discov; 2009 Jan; 4(1):28-35. PubMed ID: 19149686 [TBL] [Abstract][Full Text] [Related]
18. Peroxynitrite activates ERK via Raf-1 and MEK, independently from EGF receptor and p21Ras in H9C2 cardiomyocytes. Pesse B; Levrand S; Feihl F; Waeber B; Gavillet B; Pacher P; Liaudet L J Mol Cell Cardiol; 2005 May; 38(5):765-75. PubMed ID: 15850570 [TBL] [Abstract][Full Text] [Related]
19. Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy. Degirmenci U; Wang M; Hu J Cells; 2020 Jan; 9(1):. PubMed ID: 31941155 [TBL] [Abstract][Full Text] [Related]
20. RAS and downstream RAF-MEK and PI3K-AKT signaling in neuronal development, function and dysfunction. Zhong J Biol Chem; 2016 Mar; 397(3):215-22. PubMed ID: 26760308 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]